Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Fr | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
18.12. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial | 59 | PR Newswire | Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2
No significant safety or dose limiting toxicities... ► Artikel lesen | |
12.12. | Transcode Therapeutics stock hits 52-week low at $6.89 | 1 | Investing.com | ||
12.12. | Peering Into TransCode Therapeutics' Recent Short Interest | 1 | Benzinga.com | ||
06.12. | Transcode Therapeutics, Inc. - S-1, General form for registration of securities | 10 | SEC Filings | ||
TRANSCODE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
02.12. | Transcode Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
02.12. | Why TransCode Therapeutics (RNAZ) Stock Is Diving | 3 | Benzinga.com | ||
02.12. | TransCode Therapeutics to execute 1-for-33 reverse stock split on Dec 4 | 2 | Seeking Alpha | ||
29.11. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split | 166 | GlobeNewswire (Europe) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA... ► Artikel lesen | |
27.11. | TransCode Therapeutics announces $8M private offering | 2 | Seeking Alpha | ||
27.11. | TransCode Therapeutics, Inc. Announces $8 Million Private Placement | 2 | GlobeNewswire (USA) | ||
25.11. | Why Transcode Therapeutics (RNAZ) Stock Is Moving | 2 | Benzinga.com | ||
25.11. | TransCode Therapeutics to conduct reverse stock split | 14 | Seeking Alpha | ||
25.11. | TransCode Therapeutics approves reverse stock split | 3 | Investing.com | ||
25.11. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces 1-for-33 Reverse Stock Split | 165 | GlobeNewswire (Europe) | BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more effectively treating cancer using RNA... ► Artikel lesen | |
25.11. | Transcode Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
06.11. | Transcode Therapeutics, Inc. - 8-K, Current Report | 9 | SEC Filings | ||
05.11. | TransCode Therapeutics maintains Nasdaq listing with conditions | 14 | Investing.com | ||
05.11. | TransCode Therapeutics gets Nasdaq extension to regain compliance | 8 | Seeking Alpha | ||
05.11. | TransCode Therapeutics, Inc.: TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance | 110 | GlobeNewswire (Europe) | BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 43,015 | +0,27 % | PRESSESPIEGEL/Unternehmen: CONTINENTAL, QIAGEN, 1KOMMA5 GRAD, BOSCH, VOLKSBANKEN/SPARKASSEN | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
CONTINENTAL - Die Staatsanwaltschaft Hannover hat ihre Ermittlungsverfahren... ► Artikel lesen | |
NOVAVAX | 8,242 | -0,79 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
MOLOGEN | - | - | EQS-News: Schutzgemeinschaft der Kapitalanleger e.V.: Inhaber der Anleihe WSV 2017/2015 der Mologen AG (ISIN DE000A2DANN4 / WKN A2DANN) mit Beständen bis zu 5.000 Euro Nominalwert können anteilige Vergütung des Gemeinsamen Vertreters zurückerhalten | Emittent / Herausgeber: Schutzgemeinschaft der Kapitalanleger e.V.
/ Schlagwort(e): Anleihe/Sonstiges
Inhaber der Anleihe WSV 2017/2015 der Mologen AG (ISIN DE000A2DANN4 / WKN... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,923 | -0,97 % | Palatin Technologies, Inc.: Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy | Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
Demonstrated efficacy... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,720 | 0,00 % | Inovio Pharmaceuticals Prices $30 Mln Public Offering With Warrants | WASHINGTON (dpa-AFX) - Inovio Pharmaceuticals, Inc. (INO), a clinical-stage biotechnology company, Friday announced the pricing of a public offering of 10 million common shares and also warrants... ► Artikel lesen | |
COSCIENS BIOPHARMA | 2,220 | -11,20 % | COSCIENS Biopharma Inc. Provides Corporate Update and Highlights Pipeline Prioritization | Company leveraging core competencies to develop and commercialize natural-based products to improve health and wellness Streamlined efficiencies and cost cutting measures taken to refine operations... ► Artikel lesen | |
XOMA ROYALTY | 25,800 | +0,78 % | XOMA Preferred Shares Series A declares $0.5391 dividend | ||
T2 BIOSYSTEMS | 0,347 | +0,87 % | T2 Biosystems, Inc.: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. | LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced... ► Artikel lesen | |
PHIO PHARMACEUTICALS | 2,090 | -5,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA... ► Artikel lesen | |
MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
ORAGENICS | 0,385 | +4,60 % | ORAGENICS INC - S-1, General form for registration of securities | ||
LADRX | - | - | LadRx Corp - 10-Q, Quarterly Report | ||
TENAX THERAPEUTICS | 2,770 | 0,00 % | Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors Continuing to Enroll Patients in Phase 3 LEVEL Study with 52 Investigative... ► Artikel lesen | |
EDESA BIOTECH | 1,690 | +3,68 % | Edesa Biotech, Inc. - 10-K/A, Annual Report | ||
WINDTREE THERAPEUTICS | 0,320 | +4,37 % | WINT stock touches 52-week low at $0.32 amid steep annual decline |